| Today’s Big NewsOct 20, 2023 |
| By Max Bayer Amgen is diving deeper into phase 2 tarlatamab data after teasing the molecule's promise a couple of months ago. The asset is one of a handful of bispecific T-cell engagers that have been a focal point of the pharma's oncology work. |
|
|
|
By Angus Liu Last year, a first-of-its-kind head-to-head clinical trial between two PD-1 inhibitors went in GSK’s favor. Now, the British pharma has some new patient survival data to celebrate. |
By Andrea Park In the third quarter of this year, Intuitive saw procedures performed with its flagship da Vinci robotic surgery system surge to new heights, climbing 19% higher than the same period last year and 17% higher than the third quarter of 2019, before pandemic setbacks had set in. |
By Gabrielle Masson GSK is the latest to partake in a string of recent antibody-drug conjugate deals, dishing out $85 million cash and up to $1.4 billion in biobucks for Hansoh Pharma’s gynecologic cancer asset. |
|
November 14-15, 2023 | Free Virtual Event The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever. We are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program across two days. Providing a wide range of strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their business. Save your seat now! 
|
|
By Annalee Armstrong If anyone in Spain is wondering where the espresso machines are, they are at the exhibit hall for the European Society for Medical Oncology Congress, where one faces an important question: From which Big Pharma will I accept my complimentary espresso beverage? |
By Kevin Dunleavy Eli Lilly is going after 11 online pharmacies—including several overseas—that are allegedly importing, selling or distributing unauthorized versions of its diabetes drug Mounjaro. In a complaint filed with the U.S. International Trade Commission, Lilly has named three companies in China, three in Europe and five in the U.S. that it claims are selling “low-grade” versions of the drug. |
By Conor Hale Interventional Systems’ Micromate robot for needle-based procedures has received a new clearance from the FDA that broadens its use to CT imaging. |
By Annalee Armstrong Merck & Co. has signed a multi-billion dollar deal with Daiichi Sankyo to work on ADCs, setting a theme for the Madrid-based ESMO conference. |
By Zoey Becker The company is in talks with advisors to field interest in a potential sale, people with knowledge of the matter told Bloomberg. Other options include breaking up the business and divesting some key assets. |
By Nick Paul Taylor One of the last drugs standing at Johnson & Johnson’s slimmed-down infectious disease unit has come through another test. The oral candidate, JNJ-1802, induced antiviral activity against dengue in a human challenge study, offering J&J encouragement as it works toward data in a larger community-based trial. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients. |
|
|---|
|
|
|
Thursday, November 9, 2023 | 2pm ET / 11am PT Join us for this webinar to explore the transformative power of decentralized clinical trials. Learn how automation is reshaping the landscape of clinical development, empowering life sciences professionals to streamline processes, reduce costs, and accelerate drug development timelines. Register now. 
|
|
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Edison Ballroom, New York City |
|
|
| |
|
